dc.contributor.author
Arlt, Friederike A.
dc.contributor.author
Breuer, Ameli
dc.contributor.author
Trampenau, Elli
dc.contributor.author
Boesl, Fabian
dc.contributor.author
Kirchner, Marieluise
dc.contributor.author
Mertins, Philipp
dc.contributor.author
Sánchez-Sendín, Elisa
dc.contributor.author
Nasouti, Mahoor
dc.contributor.author
Mayrhofer, Marie
dc.contributor.author
Blüthner, Martin
dc.contributor.author
Endres, Matthias
dc.contributor.author
Prüss, Harald
dc.contributor.author
Franke, Christiana
dc.date.accessioned
2025-07-28T15:33:24Z
dc.date.available
2025-07-28T15:33:24Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/48445
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-48167
dc.description.abstract
Background: Patients suffering from neurological symptoms after COVID-19 vaccination (post-COVID-19 vaccination syndrome (PCVS)) have imposed an increasing challenge on medical practice, as diagnostic precision and therapeutic options are lacking. Underlying autoimmune dysfunctions, including autoantibodies, have been discussed in neurological disorders after SARS-CoV-2 infection and vaccination. Here, we describe the frequency and targets of autoantibodies against peripheral nervous system tissues in PCVS.
Methods: Sera from 50 PCVS patients with peripheral neurological symptoms after COVID-19 vaccination and 35 vaccinated healthy controls were used in this study. IgG autoreactivity was measured via indirect immunofluorescence assays on mouse sciatic nerve teased fibers. The frequencies of autoantibodies were compared between groups using Fisher’s exact test. Serum anti-ganglioside antibodies were measured in ganglioside blots. Autoantibody target identification was performed using immunoprecipitation coupled to mass spectrometry. Subsequent target confirmation was conducted via cell-based assays and ELISA.
Results: Compared with controls, PCVS patients had a significantly greater frequency of autoantibodies against peripheral nervous system structures (9/50(18%) vs 1/35(3%); p=0.04). Autoantibodies bound to paranodes (n=5), axons (n=4), Schmidt-Lanterman incisures (n=2) and Schwann cell nuclei (n=1). Conversely, antibodies against gangliosides were absent in PCVS patients. Target identification and subsequent confirmation revealed various subunits of neurofilaments as well as DFS-70 as autoantibody epitopes.
Conclusion: Our data suggest that autoantibodies against nervous system tissue could be relevant in PCVS patients. Autoantibodies against neurofilaments and cell nuclei with so far non-established links to this disease spectrum should be further elucidated to determine their biomarker potential.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
SARS-CoV-2 vaccination
en
dc.subject
COVID-19 vaccination
en
dc.subject
post-COVID-19 vaccination syndrome (PCVS)
en
dc.subject
autoantibody
en
dc.subject
peripheral nerve
en
dc.subject
neurofilament autoantibodies
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
High serum prevalence of autoreactive IgG antibodies against peripheral nerve structures in patients with neurological post-COVID-19 vaccination syndrome
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
1404800
dcterms.bibliographicCitation.doi
10.3389/fimmu.2024.1404800
dcterms.bibliographicCitation.journaltitle
Frontiers in Immunology
dcterms.bibliographicCitation.originalpublishername
Frontiers Media SA
dcterms.bibliographicCitation.volume
15
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
39156891
dcterms.isPartOf.eissn
1664-3224